Fred Alger Management, LLC Genmab A/S Transaction History

Fred Alger Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $2.58 Million - $3.49 Million	-78,338 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $18 Million - $25.9 Million	-582,249 Reduced 88.14%	78,338 $2.57 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $5.64 Million - $6.83 Million	167,677 Added 34.02%	660,587 $26.9 Million
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $905,456 - $1.06 Million	-27,380 Reduced 5.26%	492,910 $18 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $5.92 Million - $10 Million	295,191 Added 131.14%	520,290 $17.6 Million
Q1 2020 May 15, 2020	SELL	$17.15 - $25.22 $3.31 Million - $4.87 Million	-192,913 Reduced 46.15%	225,099 $4.77 Million
Q4 2019 Feb 14, 2020	BUY	$18.88 - $24.14 $3.53 Million - $4.51 Million	186,879 Added 80.85%	418,012 $9.33 Million
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $4.16 Million - $4.94 Million	231,133 New	231,133 $4.68 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.